The development and implementation of polygenic risk scoring algorithms for stratifying individuals for future cognitive decline due to Alzheimer's Disease in non-symptomatic and early cognitive impaired subjects

本项目将评估基于遗传的风险分层对认知正常受试者和轻度认知障碍（MCI）患者未来认知能力下降的效用。MCI可能是AD（阿尔茨海默病）的前驱状态，其中50-60%的患者有进展为AD的高风险，然而目前的AD预后方法在早期MCI中只有25-30%的准确性。缺乏有效的生物标志物阻碍了这些患者的临床管理，也阻碍了对阿尔茨海默病有用的新疗法的发展。该项目将研究大量患者和认知正常的受试者，以证明一组确定的AD风险生物标志物的有效性。这样的预后测试是必要的，使有意义的临床试验的紧急阿尔茨海默病治疗。

This project will evaluate the utility of genetic based risk stratification for future cognitive decline in cognitively normal subjects and those with Mild Cognitive Impairment (MCI). MCI may be a prodromal state for AD (Alzheimer's Disease) and 50-60% of these patients are at high risk of progression to AD, however current prognostic methods for AD are only 25-30% accurate in early MCI. The lack of validated biomarkers hampers clinical management of these patients and also the development of new therapies useful in Alzheimer's Disease. This project will study large cohorts of patients and cognitively normal subjects to demonstrate the validity of a panel of identified at-risk AD biomarkers. Such a prognostic test is essential to enable meaningful clinical trials of emergent AD therapies.